Milestone Pharmaceuticals to Host Mid-Year Update Conference Call
To access the live call by phone, dial (800) 529-3311 (domestic) or (470) 495-9164 (international) and enter the passcode 9498516. A live webcast of the call can be accessed in the News & Events section of Milestone's website at www.milestonepharma.com. An archived replay of the webcast will be available on the same website for approximately 30 days following the call.
Milestone is a Phase 3 clinical stage biopharmaceutical company dedicated to developing and commercializing the investigational new drug etripamil for the treatment of cardiovascular indications. Etripamil is a novel, potent and short-acting calcium channel blocker designed by Milestone and being developed as a rapid-onset nasal spray to be administered by the patient to terminate episodes of PSVT as they occur. Milestone is actively recruiting patients for a Phase 3 clinical trial of etripamil. Milestone is also planning to initiate a Phase 2 clinical trial in the second half of 2019 in atrial fibrillation, another rapid heart rate condition, and expect to subsequently initiate an additional Phase 2 clinical trial in angina in 2020 to establish proof-of-concept for the broader use of etripamil.
View original content to download multimedia:http://www.prnewswire.com/news-releases/milestone-pharmaceuticals-to-host-mid-year-update-conference-call-300896462.html